Teva will gain U.S. rights to two approved Samsung Bioepis biosimilars in a profit-sharing deal expected to close by the end of 2026. Teva Pharmaceutical Industries and Samsung Bioepis have signed a license and commercialization agreement that would give Teva U.S. rights to…
BioPharm International Alvotech and Advanz Pharma announced October 14, 2026, the submission of a European regulatory application for AVT29, a proposed biosimilar to Eylea 8 mg (aflibercept 114.3 mg/mL), which is marketed as Eylea HD in the United States.¹ Based on publicly available information, the…
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2026 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form…
Home / News / BioBlast® On 28 September 2026, Teva announced that it has strengthened its position in the biosimilars market with the FDA approval of its internally developed Degevma™ (denosumab-adet), biosimilar to Amgen’s Xgeva®. Degevma™ is indicated for all approved reference indications and…
Access, interchangeability, litigation, and pricing dynamics for follow‑ons.
An article joins this feed when it matches these terms. Each one is also a search of its own.